Review Article
Year: 2020 | Month: November | Volume: 7 | Issue: 11 | Pages: 484-488
A Review on Anti Obesity Drugs
Jose Mathew, Krishnaveni Kandasamy, Shanmugasundaram Rajagopal, Sambathkumar R
Department of Pharmacy Practice, J.K.K Nattraja College of Pharmacy, Komarapalayam-638183, Tamil Nadu, India
Corresponding Author: Krishnaveni Kandasamy
ABSTRACT
Obesity is a potentially life-threatening, chronic disease. As the most prevalent metabolic disorder affecting humans today, obesity requires multidisciplinary, long-term treatment. The worldwide prevalence of obesity has experienced a remarkably steady increase. Yet treatment is essential because obesity has been linked to the onset of many other chronic diseases, as well as higher rates of comorbidities and mortality. Weight loss of 5% to 10% of initial weight, accomplished by intense lifestyle treatment, decreases risk factors for cardiovascular disease (CVD), avoids or delays the progression of type 2 diabetes, and enhances other health effects of obesity. There is a need for adjunctive treatments that can help patients with dietary changes alone that are unable to lose or sustain adequate weight loss to improve health. With newly developed clinical guidelines, a better understanding of the biology of energy balance and patient variability in treatment response, and an increased availability of several monotherapy and combination anti-obesity medicines, we will start to better research and customize individualized treatments for the many different types of obesity.
Keywords: Obesity, Noradrenergic Activation, Gastrointestinal Lipase Inhibition, Serotonin Receptor Activation, Combination Therapy.
[PDF Full Text]